Proinflammatory phenotype of B10 and B10pro cells elicited by TNF-α in rheumatoid arthritis

Objectives B10 and B10pro cells suppress immune responses via secreting interleukin (IL)-10. However, their regulators and underlying mechanisms, especially in human autoimmune diseases, are elusive. This study aimed to address these questions in rheumatoid arthritis (RA), one of the most common highly disabling autoimmune diseases.Methods The frequencies and functions of B10 and B10pro cells in healthy individuals and patients with RA were first analysed. The effects of proinflammatory cytokines, particularly tumour necrosis factor (TNF)-alpha on the quantity, stability and pathogenic phenotype of these cells, were then assessed in patients with RA before and after anti-TNF therapy. The underlying mechanisms were further investigated by scRNA-seq database reanalysis, transcriptome sequencing, TNF-alpha-/- and B cell-specific SHIP-1-/- mouse disease model studies.Results TNF-alpha was a key determinant for B10 cells. TNF-alpha elicited the proinflammatory feature of B10 and B10pro cells by downregulating IL-10, and upregulating interferon-gamma and IL-17A. In patients with RA, B10 and B10pro cells were impaired with exacerbated proinflammatory phenotype, while anti-TNF therapy potently restored their frequencies and immunosuppressive functions, consistent with the increased B10 cells in TNF-alpha-/- mice. Mechanistically, TNF-alpha diminished B10 and B10pro cells by inhibiting their glycolysis and proliferation. TNF-alpha also regulated the phosphatidylinositol phosphate signalling of B10 and B10pro cells and dampened the expression of SHIP-1, a dominant phosphatidylinositol phosphatase regulator of these cells.Conclusions TNF-alpha provoked the proinflammatory phenotype of B10 and B10pro cells by disturbing SHIP-1 in RA, contributing to the disease development. Reinstating the immunosuppressive property of B10 and B10pro cells might represent novel therapeutic approaches for RA.